Hematological disorders

Global atrial fibrillation market is expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%

Posted on

Global AF market was $7.2 billion in 2015 and expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%. There are four NOACs which are indicated for the treatment of AF such as Xarelto, Eliquis, Pradaxa and Savaysa.

DelveInsight Atrial Fibrillation-Market Insights & Drugs Sales Forecast (AF) -2020 provides an overview of Atrial Fibrillation indication. The Report majorly emphasize on the global Anticoagulants market size and market size of the Anticoagulants by 7Major Markets (United States, EU5 (France, Germany, Italy, Spain, UK) and Japan). The Report also covers the market size of Atrial Fibrillation along with the market sales of the Key drugs by AF.  The Report provides comprehensive review of Market Drivers, Market barriers, Anticoagulants with coverage of detailed profile, Cost of therapy, Safety and Efficacy profiles and SWOT analysis.

With the new guideline by regulatory agencies has promoted the use of NOACs over warfarin. Atrial Fibrillation guidelines has also encouraged to use CHA2DS2-VASc score instead of the CHADS2 score for assessing stroke risk, which will cause a larger proportion of lower risk patients to receive anticoagulant treatment.

For more information email us @ info@delveinsight.com.

Advertisements

Global VTE market is expected to grow to $4.75 billion by 2020 with a compound annual growth rate (CAGR) of 2.44%

Posted on Updated on

Venous Thromboembolism- Market Insights & Drugs Sales Forecast (VTE) -2020: New Report by DelveInsight suggests that the Global VTE market was $4.2 billion in 2015 and expected to grow to $4.75 billion by 2020 with a compound annual growth rate (CAGR) of 2.44%.

DelveInsight Report “Venous Thromboembolism-Market Insights & Drugs Sales Forecast Thromboembolism indication. The Report majorly emphasize on the global market size venous thromboembolism. The Report provides Anticoagulants market size and Anticoagulants by 7 Major Markets (United States, EU5 (France, Germany, Italy, Spain, UK) and Japan) in Venous Thromboembolism indication.   The Report provides comprehensive review of Market Drivers, Market barriers, Anticoagulants with coverage of detailed profile, Cost of therapy, Safety and Efficacy profiles and SWOT analysis,

Coagulation is an important phenomenon of body to stop external bleeding but when clots are formed in blood vessels, it can be lethal. Blood clots in arteries can lead to heart attack and when formed in the blood vessels of brain can lead to stroke. Thus, anticoagulants are used to prevent the formation of blood clots in the body. Anticoagulants are proved to be a beneficial medication for the treatment of Atrial fibrillation, Deep Vein Thrombosis, Pulmonary Embolism and Stroke.  Globally the overall incidence for Venous Thromboembolism (VTE) is increasing at a higher rate. For VTE, there are approximately 1 million cases in the United States each year, many of which represent recurrent disease. The increasing epidemiology of venous thromboembolism is a key driver for the global anticoagulants market.   The global anticoagulants market is categorized based on different classes like vitamin K reductase Inhibitor, heparin, low molecular weight heparin, Factor Xa Inhibitor and thrombin inhibitors.

The VTE market is distributed among different class of anticoagulants including LMWH, NOACs and Warfarins. Once the patient diagnosed with the DVT or PE, two choices are provided ie warfarin with a parenteral anticoagulant for at least the first 5 days and until the international normalized ratio (INR) is therapeutic or novel oral anticoagulants (NOAC). Xarelto (rivaroxaban) and Eliquis (apixaban) are the preferred therapies due to less major bleeding.

For more information email us at info@delveinsight.com

DelveInsight’s Gene Therapy Reports: Launched

Posted on Updated on

Immense Growth Potential in the Gene Therapy Market!

DelveInsight has launched its Gene Therapy Report: “Gene Therapy Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape”. These Reports are the outcome of very best analytical abilities and diligent market research amalgamated with opinions of gene therapy industry experts. The report uncovers the potential of global Gene Therapy Market with insights into 15 Therapy Areas with collective pipeline of more than 300 gene therapies and the companies at their forefront.

Report Summary

These reports provide information across the gene therapy value chain covering gene therapy profiles core insights, pre-clinical data, clinical data, technology details, funding and licensing opportunities. The Report provides the gene therapy targets which are close to 190 with the target gene name, localization of gene, molecular function of target with descriptive mechanism of action. Using the propriety DelveInsight Competitive Matrix models, the report also provides the first in class market analytics providing predictive analysis of early market winners of the clinical therapies and pre-clinical therapies in a demographic presentation view.

Report Highlights

  • Global Gene Therapy Market & Pipeline Insight.
  • Trends in gene therapy partnering deals.
  • Current Prominent Research Areas and Key Players.
  • Companies Targeting Prominent Therapeutic Areas.
  • Number of Gene Therapies in Clinical Trials.
  • Number of Gene Therapies by Vectors used.
  • Technology and their innovative Companies.
  • Early Market Winners for Gene Therapy.

Scope

Reasons to buy

The Report insight covers therapy areas like; Oncology, Central nervous system, Genetic Disorders, Hematological disorders, Metabolic disorders, Ophthalmology, Cardiovascular disease, Respiratory, Immunology and other therapy areas.

For more information on Gene Therapy reports for various therapeutic areas contact us at info@delveinsight.com.

Gene Therapy’s Emergence: The “New” approach for Huntington’s disease

Posted on Updated on

Many companies have tried over the years to find a way to reverse the course of crippling neurodegenerative disorders like Huntington’s but have failed. Fortunately, Gene therapy has proven to be an answer to a wide range of serious neurodegenerative disorders like Huntington’s, and Parkinson’s etc.

The HD gene vs Gene Therapy

Huntington’s disease (HD) is an incurable, inherited disease entailing progressive loss of brain cells and motor function due to a defective gene (HD gene) which produces repeated copies of a defective protein called huntingtin, or mHTT which particularly damages a brain region called the striatum. About 30,000 Americans have Huntington’s disease (HD). Fortunately, Gene therapy which is a novel therapeutic branch of modern medicine has shown the potential for curing this disease by allowing the researchers to transfer genetic information into patient tissues and organs in order to eliminate or restore the normal functions of the diseased genes. A variety of gene therapy approaches have been tested in mouse models of HD, ranging from those aimed at ameliorating downstream pathology or replacing lost neuronal populations to more upstream strategies like gene silencing to reduce mHtt levels.

What’s already happening?

Companies like Genethon are working to provide effective treatment for curing Huntington’s disease through intrastriatal administration of a lentiviral vector carrying the gene hCNTF (Ciliary Neurotrophic Factor Human), a neuroprotective agent which protects striatal cells and maintains basal ganglia connectivity. This project is based upon ectopic expression of neurotrophic factors mediated by lentiviral vectors and is being conducted in partnership with Reference Centre for Huntington Disease as well as MIRCen (Molecular Imaging Research Center).

Another institute viz, The Children’s Hospital of Philadelphia’s (CHOP) gene therapy is also working on this disorder and recently experts have found a way to fine tune protein signals in order to provide significant relief for patients suffering from this disorder. This study is based upon adjusting the levels of a key signaling protein, in order to improve motor function and brain abnormalities in experimental animals with a form of Huntington’s disease. Neuroscientists already know that a signaling protein called mTORC1 regulates cell growth and metabolism and that it plays a key role in Huntington’s disease (HD). But the current study at The Children’s Hospital of Philadelphia’s (CHOP) Center for Cellular and Molecular Therapeutics contradicts the assumptions that inhibiting or shutting off the mTORC1 pathway, which interacts with the deleterious mHTT proteins, could help treat HD. Their study has shown that the mTORC1 pathway is already impaired in Huntington’s disease, and that improving this pathway’s functions can actually have a protective effect. However, restoring that pathway must be done very carefully as either too much or too little is detrimental. This proves that brain cells are capable of responding even after disease onset, and hints at the potential for reversing Huntington’s disease. (For details on this study, refer to http://www.ncbi.nlm.nih.gov/pubmed/25556834)

What’s hope and what’s hype?

Inspite of its checkered past gene therapy investigators in the 21st century agree that the field is enjoying a renaissance and that it has emerged with enormous potential in the field of Neurodegenerative disorders. Many companies like UniQure Biopharma, Sanofi, Oxford BioMedica etc., are operating in the field of Neurodegenerative disorders in the gene therapy domain. A growing number of partnership between companies in drug development for example between Audentes and Genethon etc., are driving the new gene therapy research. Thus leading to an increase in the global market opportunities for gene therapy with more companies focusing in this field.

DelveInsight’s Reports have already established a reputation of offering the affordable and comprehensive industry coverage and “on-the-ground” analysis in virtually every region of the world. These reports provide complete information for over 300 gene therapies which are in the pipeline for various therapy areas like; Oncology, Genitourinary, Dermatology, Central nervous system, Genetic Disorders, Hematological disorders, Metabolic disorders, Ophthalmology, Cardiovascular disease, Respiratory , Immunology, and many more…

DelveInsight’s Gene Therapy Reports cover the entire gene therapy market scenario including technology assessments, licensing opportunities, collaborations, market trends, pipeline coverage and competitive landscape. The report essentially provides DelveInsight’s proprietary market and pipeline analytics which identifies the front runners of all therapeutic areas. It also identifies the potential market movers and future regulatory landscape. These reports are designed to provide the clients with the means to out produce their competitors by developing a product that makes history.

For more info on Gene Therapy Reports for various Therapeutic areas contact us at: info@delveinsight.com.

Are you ready to embrace Gene Therapy? DelveInsight’s Gene Therapy Reports

Posted on Updated on

Gene Therapy: The “Big Value” Market!

Gene therapy has been under scientific research for over 2 decades, but viable therapies have yet to gain commercial acceptance due to safety and delivery-related issues. However, Pfizer’s move and some other recent developments in the industry suggest that the therapy may be coming off age. With the superlatively well-funded biotech Moderna Therapeutics raising another $450 million in venture cash, for its mRNA based proprietary approach to treat previously undruggable targets in a wide range of disease areas (with 45 preclinical programs in its pipeline), it has become clear that the Gene therapy market is going to be of great interest for many companies globally due to the possibility of a permanent cure that it offers for any of the more than 10,000 human diseases caused by a defect in a single gene.

About Gene Therapy

Gene therapy aims to fix a genetic problem at its source. By adding a corrected copy of a defective gene, gene therapy promises to help diseased tissues and organs work properly. This approach is different from traditional drug-based approaches, which may treat symptoms but not the underlying genetic problems. Put simply, it introduces a “good” gene into a person who has a disease caused by a “faulty” gene.

Gene Therapy Reports: Understanding the potential of Gene Therapy Market

During the past two decades gene therapy has made important medical advances. Within this short time span, it has moved from the conceptual stage to technology development and laboratory research to clinical translational trials for a variety of deadly diseases. The researchers have learned from their mistakes and developed much more realistic approach and solutions to many of the problems which led to major clinical and commercial successes. It has become an upcoming research area in 21st century with the industry’s collective pipeline brimming with therapies close to 300.

There is a significant increase in the companies coming up with gene therapies for various therapeutic areas such as Novartis, GlaxoSmithKline, Sanofi, UniQure Biopharma, Oxford BioMedica etc., which are operating in the gene therapy domain. Moreover recent academic and industry partnerships for example between Celgene Corporation and Baylor College of Medicine, GSK and the Roswell Park Cancer Institute etc., are driving new gene therapy research.

DelveInsight’s Gene Therapy Reports

DelveInsight’s Gene Therapy Reports cover the entire gene therapy market insights including technology assessments, licensing opportunities, collaborations, market trends, pipeline coverage and competitive landscape. The report essentially provides DelveInsight’s proprietary market and pipeline analytics which identifies the front runners of all therapeutic areas. It also identifies the potential market movers and future regulatory landscape. These reports provide complete insight over all the therapy areas associated with gene therapy like; Oncology, Genitourinary, Dermatology, Central nervous system, Genetic Disorders, Hematological disorders, Metabolic disorders, Ophthalmology, Cardiovascular disease, Respiratory , Immunology, and many more…

DelveInsight’s Gene Therapy Reports: Reasons to buy

  • Complete Market and Pipeline intelligence and complete understanding over therapeutics development for gene therapy.
  • Devise corrective measures for pipeline projects by understanding gene therapies for specific therapy areas.
  • Developing strategic initiatives to support your gene therapy development activities.
  • Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
  • Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Evaluate the marketing and pipeline strategy for gene therapies and their Funding availabilities.
  • Identifying the upcoming leaders in the gene therapy market in the coming years.
  • Getting a first mover advantage by identifying the early market winners for clinical and preclinical gene therapies.

For more info on Gene Therapy Reports for various Therapeutic areas refer to the following links:

DelveInsight’s Oncology based Gene Therapy Reports

DelveInsight’s Otolaryngology based Gene Therapy Reports

DelveInsight’s Central Nervous System based Gene Therapy Reports

DelveInsight’s Genitourinary & Sex hormones based Gene Therapy Reports

DelveInsight’s Dermatology based Gene Therapy Reports

DelveInsight’s Genetic disorders based Gene Therapy Reports

DelveInsight’s Gastrointestinal based Gene Therapy Reports

DelveInsight’s Infectious disorders based Gene Therapy Reports

DelveInsight’s Metabolic disorders based Gene Therapy Reports

DelveInsight’s Musculoskeletal disorders based Gene Therapy Reports

DelveInsight’s Cardiovascular disorders based Gene Therapy Reports

DelveInsight’s Immunology based Gene Therapy Reports

DelveInsight’s Respiratory disorders based Gene Therapy Reports

DelveInsight’s Hematological disorders based Gene Therapy Reports

DelveInsight’s Ophthalmologic disorders based Gene Therapy Reports

DelveInsight’s Hematological disorders based Gene Therapy Reports

Posted on Updated on

Gene Therapy to “target” Hematological disorders!

About Hematological disorders

Hematology is the study of blood in health and disease. It includes problems with the red blood cells, white blood cells, platelets, blood vessels, bone marrow, lymph nodes, spleen, and the proteins involved in bleeding and clotting (hemostasis and thrombosis).

Haemoglobin comprises of four globin chains: fetal haemoglobin (Hb F) which has two α and two gamma chains (α2γ2) and adult haemoglobin (Hb A) which has two α and two β chains (α2β2). Genes in the α-globin and β-globin gene clusters (on chromosomes 16 and 11) control globin-chain production. However, due to spontaneous mutation, haemoglobin gene variants are present at low prevalence (carriers 1–1.5/1000) in all sizeable populations. They fall into two broad groups – structural variants that change the amino acid sequence and produce an unusual haemoglobin, and thalassaemias that lower or abolish production of globin chains. Prevention of hematological disorders is making only a small impression as affected birth prevalence is estimated at 2.55 per 1000. The yardstick of under-5 mortality depicts the broad effect of hematological disorders on health, because most affected children die in early childhood and most survivors have chronic disease. It has long been the hope that one day it would be possible to cure these diseases by fixing the mutation that causes the disease and thus affect a cure. As a result of the various technological advancements over the past decade, we now know the identities of the specific genes involved in vast majority of these hematological diseases. Gene therapy aims to correct this disease process by restoring, modifying or enhancing cellular functions through the introduction of a functional gene into a target cell.

Gene Therapy: Role in Hematological disorders

The compelling desire to target therapy at a molecular level has resulted in the emergence of new direction in medicine, called gene therapy. The simplicity of the basic concepts of gene therapy together with exciting early results in animal models have fuelled great enthusiasm for this field. Gene therapy has emerged as an avenue of hope for many hematological disorders that cannot be effectively treated with drugs, recombinant therapeutic proteins or transplantation. In addition, gene therapy has the potential to transform the lives of those patients who are dependent on life-long parenteral therapy with recombinant proteins or blood and its products. A number of preclinical and clinical studies have been conducted with the aim of developing gene therapy for hemophilia, Fanconi anemia, sickle cell disease, beta-thalassemia, chronic granulomatous disease, and other hematological disorders. Results from these studies and from preclinical studies preceding the trial demonstrate that it is possible to safely administer high doses of a viral vector in vivo. Thus, making gene therapy a promising candidate for treating Hematological disorders.

Gene Therapy: The Market Scenario

Gene therapy is an emerging field which has the potential of altering the world of diagnosis, treatment and drug discovery. Gene therapy treatments have shown promise in the field of haematology as a result the market opportunities for gene therapy in the field of hematological disorders have been on a rise with large biopharmaceutical companies such as Genethon, uniQure biopharma. etc. operating in this domain. A growing number of partnership between companies in drug development for example between Anges and Daiichi Sankyo etc., are driving the new gene therapy research. The industry’s collective pipeline is brimming with 300+ therapies for various therapeutic areas. However, the immediate challenges of the field as it moves toward clinical trials are to optimize gene transfer and to minimize the adverse consequences that can result from random integration of vectors into the genome by improving current vector design or developing novel vectors.

DelveInsight’s Gene Therapy Reports

DelveInsight’s Gene Therapy Reports cover the entire gene therapy market insights for hematological disorders including technology assessments, licensing opportunities, collaborations, market trends, pipeline coverage and competitive landscape. The report essentially provides DelveInsight’s proprietary market and pipeline analytics which identifies the front runners in this therapeutic area. It also identifies the potential market movers and future regulatory landscape.

Break the Gene Therapy Barrier with DelveInsight’s Gene Therapy Reports

Posted on Updated on

Gene Therapy: The Future is here!

Scientific research and clinical trials aren’t glamorous, but they are essential for effective treatments and perhaps ultimately a cure for various debilitating diseases like cancer etc. Gene therapy’s potential to revolutionize medicine in the future is exciting, and one day it may be possible to treat an unborn child for a genetic disease even before symptoms appear.

About Gene Therapy

Gene Therapy involves using genes as medicines by transferring a therapeutic gene through a genetically engineered vector into the targeted cells of a patient to repair an unhealthy gene thus help in curing disease by synthesizing correct proteins. Put simply, it introduces a “good” gene into a person who has a disease caused by a “bad” gene.

Gene Therapy: The Past

Gene therapy has had rather a bad decade as it got off with two unapproved trials in the early 70s and early 80s in which first one was an attempt made to treat two young girls with arginase deficiency syndrome using in vivo gene therapy with wild-type Shope papilloma virus in order to replace the missing arginase enzyme in the patients and the second one was ex vivo gene therapy for ß-thalassemia, a bone marrow transplant using marrow cells treated with a ß-globin-containing plasmid, again in two patients. Unfortunately in neither case was any real follow-up reported, since both trials were stopped. The final blow to Gene therapy field came in September 1999 with the widely publicized death of an eighteen-year-old man undergoing gene therapy for a liver disease at the University of Pennsylvania, an event that brought the scrutiny of the press onto the world of gene therapy.

But at the turn of the millennium, through the year 2000, reports of the first successful trials began to be heard indicating that real success may be just around the corner: factor IX for hemophilia, transduced stem cells for X-linked SCID, and oncolytic vectors etc. In the ten year cycle of failed clinical trials the researchers learned from their mistakes and developed much more realistic approach and solutions to many of the problems which led to major clinical and commercial successes.

Gene Therapy: The Present Scenario

The past two decades have seen significant increase in the companies coming up with gene therapies for various therapeutic areas. The human clinical trials are majorly performed for the oncology indications. However, the market for gene therapy is currently in the experimental stages due the risk involved with the use of genes designed in laboratory growth as well as the regulatory approval of products which are currently in clinical trials resulting in only three drugs hitting the market in past decade. Inspite of this, Gene therapy has proved to be a promising approach for many incurable diseases with many promising therapies in phase III clinical trials.

Gene Therapy: The Market Scenario

Many companies have started investing in and researching on gene therapy due to its promising effects. A growing number of Big Pharma companies are partnering in drug development with innovation-rich biotech firms. Large Pharmaceutical and Biotechnology giants, such as Novartis, GlaxoSmithKline, Sanofi etc., are operating in the gene therapy domain. Moreover recent academic and industry partnerships for example between Celgene Corporation and Baylor College of Medicine, GSK and the Roswell Park Cancer Institute etc., are driving new gene therapy research. The industry’s collective pipeline is brimming with 300+ drugs of which oncology collectively accounts for 29 % of gene therapies in pipeline. Despite of high cost involved recent years have seen many companies coming up for the treatment of deadly diseases. The global market opportunities for gene therapy have risen drastically and continue to be great area of interest for many companies globally.

DelveInsight’s Gene Therapy Reports

DelveInsight’s Gene Therapy Reports cover the entire gene therapy market insights including technology assessments, licensing opportunities, collaborations, market trends, pipeline coverage and competitive landscape. The report essentially provides DelveInsight’s proprietary market and pipeline analytics which identifies the front runners of all therapeutic areas. It also identifies the potential market movers and future regulatory landscape.

The Report insight covers therapy areas like; Oncology, Central nervous system, Genetic Disorders, Hematological disorders, Metabolic disorders, Ophthalmology, Cardiovascular disease, Respiratory and Immunology and many more…